Ignite Creation Date:
2025-12-24 @ 10:09 PM
Ignite Modification Date:
2025-12-28 @ 2:58 AM
Study NCT ID:
NCT05300035
Status:
RECRUITING
Last Update Posted:
2024-12-27
First Post:
2022-01-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000163', 'term': 'Acquired Immunodeficiency Syndrome'}, {'id': 'D007239', 'term': 'Infections'}], 'ancestors': [{'id': 'D015658', 'term': 'HIV Infections'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D015229', 'term': 'Sexually Transmitted Diseases, Viral'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}, {'id': 'D016180', 'term': 'Lentivirus Infections'}, {'id': 'D012192', 'term': 'Retroviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D012897', 'term': 'Slow Virus Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007153', 'term': 'Immunologic Deficiency Syndromes'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000080908', 'term': 'Broadly Neutralizing Antibodies'}, {'id': 'D000077330', 'term': 'Saline Solution'}], 'ancestors': [{'id': 'D057134', 'term': 'Antibodies, Neutralizing'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D000077324', 'term': 'Crystalloid Solutions'}, {'id': 'D007552', 'term': 'Isotonic Solutions'}, {'id': 'D012996', 'term': 'Solutions'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 69}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-04-11', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-12', 'completionDateStruct': {'date': '2028-12-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-12-23', 'studyFirstSubmitDate': '2022-01-03', 'studyFirstSubmitQcDate': '2022-03-18', 'lastUpdatePostDateStruct': {'date': '2024-12-27', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-03-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12-10', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of participants with plasma HIV-1 RNA below 400 cp/mL 24 weeks following ATI (W24 ATI), in the confirmed absence of ART.', 'timeFrame': 'at Week 24 of antiretroviral treatment interruption period (ATI)', 'description': 'These participants will be considered as post-treatment controllers.'}], 'secondaryOutcomes': [{'measure': 'Tolerance of bNAbs infusion : Number of clinical and biological adverse event (AE)', 'timeFrame': 'from date of inclusion to the last follow-up visit date, up to 148 weeks', 'description': 'Number of clinical and biological AE during follow-up. Abnormal laboratory values will be identified as those outside values defined by the DAIDS scale'}, {'measure': 'Tolerance of bNAbs infusion : Nature and Grade of clinical and biological AE', 'timeFrame': 'from date of inclusion to the last follow-up visit date, up to 148 weeks', 'description': 'Grade of clinical and biological adverse during follow-up. The intensity of all AE (serious and non-serious) will be graded using the DAIDS AE Grading Table Corrected Version 2.1-July 2017'}, {'measure': 'Tolerance of bNAbs infusion : Time of clinical and biological adverse event (AE)', 'timeFrame': 'from date of inclusion to the last follow-up visit date, up to 148 weeks'}, {'measure': 'Proportion of participants resuming ART within the first 24 weeks of ART interruption, according to the reason for resuming.', 'timeFrame': 'at Week 24 of antiretroviral treatment interruption period (ATI)'}, {'measure': 'Time to potential ART resumption for non-controllers.', 'timeFrame': 'from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption date, assessed up to 48 weeks following ATI'}, {'measure': 'Clinical and immulogical criteria during follow-up: Proportion of participants with clinical symptoms.', 'timeFrame': 'during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)'}, {'measure': 'Clinical and immulogical criteria during follow-up: Evolution of CD4, CD8 (levels and %) and CD4/CD8 ratio.', 'timeFrame': 'during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)'}, {'measure': 'Clinical and immulogical criteria during follow-up: Evolution of inflammation markers levels.', 'timeFrame': 'biological parameters levels during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)', 'description': 'physiological parameters levels will be studied: IP10, TGFβ, IL-7, IL-10, IL-12, IL-15, IL-18, Citrulline, sCD14, sCD163, TNF-α'}, {'measure': 'Immulogical criteria : Changes in the magnitude and quality of HIV-specific T cell responses and humoral responses.', 'timeFrame': 'physiological parameters levels during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)', 'description': 'physiological parameters levels will be studied: frequency and functionality of T cells responding to HIV peptides measured by intracellular cytokine staining, surface expression of activation and differentiation markers, HIV suppressive capacity upon co-culture with autologous infected cells'}, {'measure': 'Virological criteria during follow-up: Plasma HIV-1 RNA and HIV-1 DNA level and cell-associated HIV RNA transcripts changes.', 'timeFrame': 'during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)'}, {'measure': 'Virological criteria : Proportion of participant with plasma HIV-1 RNA < 50 cp/mL at 12- and 24-weeks following ART interruption.', 'timeFrame': 'at Week 12 and Week 24 of antiretroviral treatment interruption period (ATI)'}, {'measure': 'Virological criteria : Cumulative plasma viremia during ART interruption.', 'timeFrame': 'from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption, assessed up to 48 weeks following ATI'}, {'measure': 'Virological criteria : in case of ART resumption, time from date of ART interruption begining to date of first HIV-1 RNA ≥ 50 copies/mL', 'timeFrame': 'from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption, assessed up to 48 weeks following ATI'}, {'measure': 'Virological criteria : in case of ART resumption, proportion of participant with plasma HIV-1 RNA < 50 copies/mL within 24 weeks of ATI.', 'timeFrame': 'from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption, assessed up to 48 weeks following ATI'}, {'measure': 'Virological criteria : Evolution of total HIV-1 DNA and cell-associated HIV-1 RNA by US q-PCR and predictive value on post- ART interruption evolution.', 'timeFrame': 'during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)'}, {'measure': 'Virological criteria : Evolution of detection proportion and level of cell-associated HIV-1 RNA.', 'timeFrame': 'during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)'}, {'measure': 'Virological criteria : Qualitative and quantitative changes in the persistent viral reservoir.', 'timeFrame': 'physiological parameters levels during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)', 'description': 'physiological parameters levels will be studied: total cell associated HIV-DNA, integrated HIV-DNA, proportion of replication competent vs defective proviruses'}, {'measure': 'Dosages of bNAbs performed during follow-up.', 'timeFrame': 'during ART follow-up (Week 1,Week 12, Week 24, Week 36), and antiretroviral treatment interruption period (Day 0, Week 12, Week 24)'}, {'measure': 'Criteria related to the risk of HIV-1 transmission : Proportion of participants reporting to use condoms during sexual intercourses', 'timeFrame': 'from date of inclusion to the last follow-up visit date, up to 148 weeks'}, {'measure': 'Criteria related to the risk of HIV-1 transmission : Proportion of participants reporting to have proposed PrEP at their partners.', 'timeFrame': 'from date of inclusion to the last follow-up visit date, up to 148 weeks'}, {'measure': 'Social sciences criteria : Proportion of patients satisfied with their participation and the associated factors', 'timeFrame': 'from date of inclusion to the last follow-up visit date, up to 148 weeks'}, {'measure': 'Social sciences criteria : Impact of the participation in the trial on participant quality of life and quality of sexual life', 'timeFrame': 'from date of inclusion to the last follow-up visit date, up to 148 weeks', 'description': 'Through statistical analyses of some self-administered questionnaires items (in particular the SF12.v2 scale for quality of life) and thematic analyses of semi-directive individual interviews we will highlight the impact of the participation in the trial.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['HIV/AIDS and Infections']}, 'descriptionModule': {'briefSummary': 'RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART initiation.', 'detailedDescription': 'The study proposes to test an intervention consisting of dual long-acting HIV-specific broadly neutralizing antibodies (3BNC117-LS \\& 10-1074-LS ) + ART, at primary HIV-1 infection, and to compare it to ART only regarding HIV-1 replication.\n\nThe study aims to enrol 69 participants in French (Ile-de-France) clinical centres. Participants will have been diagnosed with primary HIV-1 infection, will start ART during early phase of Primary HIV infection, and will interrupt ART 52 weeks later.\n\nStudy duration will vary by participant, depending on the time of ART interruption and the time to viral rebound.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Confirmed primary HIV-1 infection diagnostic\n* Aged ≥18 to ≤70 years old at screening\n* Willing to use use an effective method of contraception from the inclusion until the end of the follow-up in the trial\n* Negative plasmatic beta human chorionic gonadotropin (β-HCG) pregnancy test, when applicable\n* Agree not to seek pregnancy including through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit, when applicable\n* Informed and written signed consent\n* Participant with regular health insurance\n* Willing to accept the trial constraints (travel for IMP administration and ART interruption)\n* Willing to be vaccinated against COVID-19 according to recommandations\n\nExclusion Criteria:\n\n* Participation in any other clinical trial requiring additional blood sampling Participation in an observational study without additional blood sampling is permitted\n* Participants in whom condom use or PrEP use by the partner will be difficult or impossible\n* Pregnant or breastfeeding patient\n* Participants under guardianship or curatorship\n* Any condition or infection, including HCV, HBV, SARS-CoV-2 or known M. tuberculosis active infection History of ischemic heart disease (myocardial infarction, stable or unstable angina, stroke)\n* Current or past history of cancer, excluding squamous cell skin cancers\n* History or acute known inflammatory ophthalmic affection (uveitis, choroiditis, optic neuropathy)\n* Any medical condition that contraindicates ART interruption\n* Concomitant or previous conditions that preclude injection of monoclonal antibodies\n* History of systemic corticosteroids, immunosuppressive and anti-cancer medications within the last 6 months\n* History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions\n* Individuals with any contraindication (including hypersensitivity reaction) to 3BNC117-LS and 10-1074-LS infusion\n* Prothrombin \\< 50%\n* Creatinine clearance \\< 60mL/mn (Cockroft)\n* ASAT or ALAT or bilirubine (total et conjugated) ≥ 10 times the upper limit of normal\n* Patient with an isolated HIV-2 viral strain\n* Planned absence that could affect participation in the trial (travel abroad, relocation, impending transfer...)'}, 'identificationModule': {'nctId': 'NCT05300035', 'acronym': 'RHIVIERA-02', 'briefTitle': 'Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control', 'organization': {'class': 'OTHER_GOV', 'fullName': 'ANRS, Emerging Infectious Diseases'}, 'officialTitle': 'A Randomised Phase II Placebo-controlled Trial of Antiretroviral Therapy (ART) Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo During Primary HIV-1 Infection to Study the Impact on Post-treatment HIV Control.', 'orgStudyIdInfo': {'id': 'ANRS 176 RHIVIERA-02'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'bNAbs', 'description': 'ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).', 'interventionNames': ['Drug: Recombinant human monoclonal antibody (bNAbs)']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'ART plus placebo (saline solution) at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Recombinant human monoclonal antibody (bNAbs)', 'type': 'DRUG', 'otherNames': ['10-1074-LS and 3BNC117-LS'], 'description': '1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \\& 10-1074LS) between Day 7 and Day 10.\n2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.\n3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.\n4. ART resumption, if participant encounters at least one ART resumption criteria.', 'armGroupLabels': ['bNAbs']}, {'name': 'Placebo', 'type': 'DRUG', 'otherNames': ['Saline solution'], 'description': '1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.\n2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.\n3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.\n4. ART resumption, if participant encounters at least one ART resumption criteria.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '93000', 'city': 'Bobigny', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Brigitte Gbaguidi', 'role': 'CONTACT', 'email': 'brigitte.gbaguidi@aphp.fr'}, {'name': 'Olivier Bouchaud', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpial Avicenne - SMIT', 'geoPoint': {'lat': 48.90982, 'lon': 2.45012}}, {'zip': '92140', 'city': 'Clamart', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Sandrine Poirier', 'role': 'CONTACT', 'email': 'sandrine.poirier@aphp.fr'}, {'name': 'Sophie Abgrall', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Antoine Béclère', 'geoPoint': {'lat': 48.80299, 'lon': 2.26692}}, {'zip': '92110', 'city': 'Clichy', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Abdelmoula Becharef', 'role': 'CONTACT', 'email': 'abdelmoula.becharef@aphp.fr'}, {'name': 'Agnès Villemant Ululag', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Beaujon - Service de médecine interne', 'geoPoint': {'lat': 48.90018, 'lon': 2.30952}}, {'zip': '94010', 'city': 'Créteil', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Laurent Richier', 'role': 'CONTACT', 'email': 'laurent.richier@chicreteil.fr'}, {'name': 'Valérie Garrait', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHI Créteil - HdJ', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'zip': '92380', 'city': 'Garches', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Rezak Mahrez', 'role': 'CONTACT', 'email': 'rezak.mahrez@aphp.fr'}, {'name': 'Pierre De Truchis', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Raymond Poincaré - SMIT', 'geoPoint': {'lat': 48.84226, 'lon': 2.18232}}, {'zip': '94275', 'city': 'Le Kremlin-Bicêtre', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Véronique Godard', 'role': 'CONTACT', 'email': 'veronique.godard@aphp.fr'}, {'name': 'Cécile Goujard', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Bicêtre - HdJ - Médecine interne', 'geoPoint': {'lat': 48.81471, 'lon': 2.36073}}, {'zip': '75004', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Marie-Josée Dulucq', 'role': 'CONTACT', 'email': 'marie-josee.dulucq@aphp.fr'}, {'name': 'Jean-Paul Viard', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Hôtel - Dieu', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75004', 'city': 'Paris', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Anne Rachline', 'role': 'CONTACT', 'email': 'anne.rachline@aphp.fr'}, {'name': 'Laurence Weiss', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Hôpital Hôtel Dieu - Service d'immunologie clinique", 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75013', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Yasmine Dudoit', 'role': 'CONTACT', 'email': 'yasmine.dudoit@aphp.fr'}, {'name': 'Naima Hamani', 'role': 'CONTACT', 'email': 'naima.hamani@aphp.fr'}, {'name': 'Romain Palich', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Pitié-Salpêtrière - SMIT', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75475', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Guylaine Alexandre', 'role': 'CONTACT', 'email': 'guylaine.alexandre@aphp.fr'}, {'name': 'Pierre Sellier', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Lariboisière - Service de médecine interne A', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75475', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Cylia Imekhlaf', 'role': 'CONTACT', 'email': 'cylia.imekhlaf@aphp.fr'}, {'name': 'Caroline Lascoux-Combe', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Saint- Louis - SMIT', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75571', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Bénédicte Lefebvre', 'role': 'CONTACT', 'email': 'benedicte.lefebvre2@aphp.fr'}, {'name': 'Julie Lamarque', 'role': 'CONTACT', 'email': 'julie.lamarque@aphp.fr'}, {'name': 'Karine Lacombe', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Saint-Antoine - SMIT', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75743', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Carole Louisin', 'role': 'CONTACT', 'email': 'carole.louisin@aphp.fr'}, {'name': 'Claudine Duvivier', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Necker - SMIT', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75877', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Lynda Chalal', 'role': 'CONTACT', 'email': 'lynda.chalal@aphp.fr'}, {'name': 'Jade Ghosn', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Bichat - Claude Bernard - SMIT', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75970', 'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Pelagie Thibaut', 'role': 'CONTACT', 'email': 'pelagie.thibaut@aphp.fr'}, {'name': 'Christia Palacios', 'role': 'CONTACT', 'email': 'christia.palacios@aphp.fr'}, {'name': 'Gilles Pialloux', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Tenon - SMIT', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '92151', 'city': 'Suresnes', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Amina Fadli', 'role': 'CONTACT', 'email': 'a.fadli@hopital-foch.com'}, {'name': 'David Zucman', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre médico chirurgical Foch - Suresnes', 'geoPoint': {'lat': 48.87143, 'lon': 2.22929}}, {'zip': '94195', 'city': 'Villeneuve-Saint-Georges', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Laurent Richier', 'role': 'CONTACT', 'email': 'laurent.richier@chiv.fr'}, {'name': 'Pauline Caraux Paz', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHI Villeneuve-Saint-Georges - SMIT', 'geoPoint': {'lat': 48.73219, 'lon': 2.44925}}], 'centralContacts': [{'name': 'Mathilde Ghislain, MSc', 'role': 'CONTACT', 'email': 'mathilde.ghislain@inserm.fr', 'phone': '+331 45 59 52 29'}, {'name': 'Nicolas Leturque, MSc', 'role': 'CONTACT', 'email': 'nicolas.leturque@inserm.fr', 'phone': '+331 45 59 51 93'}], 'overallOfficials': [{'name': 'Cécile Goujard, Pr', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Assistance Publique - Hôpitaux de Paris'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'ANRS, Emerging Infectious Diseases', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'Rockefeller University', 'class': 'OTHER'}, {'name': 'Institut Pasteur', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}